In English | En español
Questions About Cancer? 1-800-4-CANCER

Colorectal Cancer Screening (PDQ®)

  • Updated: 07/24/2014

Table 3. Randomized Controlled Screening Trials: Fecal Occult Blood Testing

Site Population Size  Positivity Rate (%)  % Cancers Localizeda Testing Interval Relative Mortality Reduction 
a% Localized = T1–3 N0 M0.
Screened Control
Minnesota [5,28]48,000Unrehydrated: 2.4%5953Annual33%
Rehydrated: 9.8%Biennial21%
United Kingdom [10]150,000Unrehydrated: 2.1%5244Biennial15%
Denmark [14]62,000Unrehydrated: 1.0%5648Biennial18%
Sweden [29]68,308Unrehydrated: 1.9%525016%
Rehydrated: 5.8%

References

  1. Mandel JS, Church TR, Ederer F, et al.: Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 91 (5): 434-7, 1999.  [PUBMED Abstract]

  2. Hardcastle JD, Chamberlain JO, Robinson MH, et al.: Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348 (9040): 1472-7, 1996.  [PUBMED Abstract]

  3. Kronborg O, Fenger C, Olsen J, et al.: Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 348 (9040): 1467-71, 1996.  [PUBMED Abstract]

  4. Mandel JS, Bond JH, Church TR, et al.: Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 328 (19): 1365-71, 1993.  [PUBMED Abstract]

  5. Kewenter J, Björk S, Haglind E, et al.: Screening and rescreening for colorectal cancer. A controlled trial of fecal occult blood testing in 27,700 subjects. Cancer 62 (3): 645-51, 1988.  [PUBMED Abstract]